Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

doi:10.1158/1078-0432.CCR-09-1298

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2009

Liu Phillip C C, Caulder Eian, Li Jun, Waeltz Paul, Margulis Alex, Wynn Richard, Becker-Pasha Mary, Li Yanlong, Crowgey Erin, Hollis Gregory, Haley Patrick, Sparks Richard B, Combs Andrew P, Rodgers James D, Burn Timothy C, Vaddi Kris, Fridman Jordan S

Abstract excerpt

PURPOSE: Deregulation of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway is a hallmark for the Philadelphia chromosome-negative myeloproliferative diseases polycythemia vera, essential thrombocythemia, and primary myelofibrosis. We tested the efficacy of a selective JAK1/2 inhibitor in cellular and in vivo models of JAK2-driven malignancy. EXPERIMENTAL DESIGN: A novel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis

Share to Enzyme Inhibitors

Share to Inhibitory Concentration 50

Share to Janus Kinase 1

Share to Janus Kinase 2

Share to Neoplasm Transplantation

Share to Polycythemia Vera

Source

Open in PubMed

Identifiers

PMID: 19887489
DOI: 10.1158/1078-0432.CCR-09-1298

Genes

JAK1
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.PMID 19887489Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.Semantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Semantic proximity Read ↗

Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms.Semantic proximity Read ↗

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read ↗

JAK-mutant myeloproliferative neoplasms.Semantic proximity Read ↗

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.Semantic proximity Read ↗

Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of CancerSemantic proximity Read ↗

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.